RSLV-132   Click here for help

GtoPdb Ligand ID: 10412

Synonyms: RSLV132
Immunopharmacology Ligand
Compound class: Peptide
Comment: RSLV-132 is a fully human biologic fusion protein that is comprised of human RNase fused to the Fc domain of human IgG1 [1]. The peptide sequence of RSLV-132 has not yet been formally disclosed. It is designed to digest circulating extracellular RNA autoantigens that are known to trigger inflammatory responses in some chronic autoinflammatory conditions. RSLV-132 is proposed for anti-inflammatory and immunomodulatory activities in such conditions. It may also be effective in reducing viral RNA load and/or persistence in virus reservoirs.
No information available.
Summary of Clinical Use Click here for help
RSLV-132 was initially progressed to clinical studies for potential to treat the autoimmune conditions, systemic lupus erythematosus (SLE) [2-3], and later for Sjogren's syndrome. It was also repositioned as a novel long COVID therapy.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02660944 A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE) Phase 2 Interventional Resolve Therapeutics
NCT04944121 Phase 2 Study of RSLV-132 in Subjects With Long COVID Phase 2 Interventional Resolve Therapeutics
NCT02194400 Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus Phase 1 Interventional Resolve Therapeutics 1
NCT06440525 A Study of RSLV-132 in Females with Sjögren's Syndrome Phase 2 Interventional Resolve Therapeutics
NCT03247686 A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome Phase 2 Interventional Resolve Therapeutics 6